Neurology

CGRP drugs and new PACAP targets are reshaping acute and preventive therapy.

The new drug application's submission is supported by data from the phase 3 clinical studies SynAIRgy and LunAIRo.

If approved, AXS-12 would be a potentially valuable new option for a symptom that significantly impairs the daily functioning of those with narcolepsy.

TV-44749 is a subcutaneous long-acting injectable form of olanzapine that is effective in schizophrenia while avoiding risks seen with the intramuscular formulation.

This approval marks the first time patients can begin treatment with home administration either by themselves or their caregiver.

Compared with placebo, adult patients with ADHD and comorbid anxiety had greater change from baseline in AISRS total score at week 8.

The European Commission approved tolebrutinib as the first therapy targeting disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (SPMS).

Gonzelez describes advances in Alzheimer disease diagnostics and disease-modifying therapies and highlights the critical role pharmacists play in medication management, caregiver education, and improving treatment access.

Giants of MS is one of the field’s most prestigious honors, awarded at the 2026 Consortium for MS Centers (CMSC) 2026 Annual Meeting.

At Duke Neurological Disorders Clinic, Jenelle Hall Montgomery, PharmD, BCACP, CPP, isn’t just advising on medications—she’s prescribing them, switching them, and managing the full arc of a patient’s therapy.

Both slow and fast transition periods were safe and effective, with minimal adverse events.

PET scans show long COVID mood and brain fog link to limbic activity, not widespread brain inflammation, reshaping COVID-19 treatment targets.

Subgroup data show ofatumumab sharply cuts relapses, MRI lesions, and neurodamage markers in highly active relapsing MS vs teriflunomide.

Genetic analysis links low vitamin D and earlier menarche to higher AQP4-IgG NMOSD risk, reshaping prevention and sparking calls for diverse studies.

Phase 3 FENhance trial data show CNS-penetrant BTK inhibitor fenebrutinib cuts relapses and MRI lesions in relapsing MS.

New data show ublituximab boosts MS quality of life fast and may start in 1 infusion for relapsing multiple sclerosis.

New data show cladribine tablets deliver strong relapse control and reassuring safety in older adults with relapsing multiple sclerosis, including 65 years and older.

Frexalimab shows 3-year MRI and relapse control in relapsing multiple sclerosis with stable immunity and reassuring safety.

Amid the evolving landscape of MS treatments, there is an increasing emphasis on strategic approaches to early intervention and switching therapies.

ENHANCE trial data show ublituximab-xiiy can start with a single bioequivalent infusion, easing multiple sclerosis treatment initiation.

Identifying inappropriate OTC medications and recommending safer pharmacotherapy treatments are important roles for pharmacists.

Neurology trial tests low-dose lithium for MCI and Alzheimer risk; results miss primary end points but hint at slower verbal memory decline.

MS care shifts to smoldering progression and biomarkers; learn how pharmacists guide DMT choices, monitoring, and emerging BTK inhibitor therapy.

Neurology pharmacists drive safer medication changes, boost access and financial assistance, and deliver major cost savings through high-impact outpatient pharmacist intervention.

This approval marks the first high-efficacy B-cell depletion therapy approved for pediatric patients 10 years and older.